Cite
HARVARD Citation
Blaum, C. et al. (2021). The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. European journal of preventive cardiology. pp. 47-56. [Online].